The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family ...
Adding a PD-1 inhibitor to standard of care improved disease-free survival (DFS) in stage III soft-tissue sarcoma of the extremity, a randomized trial showed. In patients with mostly undifferentiated ...
Against the backdrop of a case report, pembrolizumab was investigated as immunotherapy for undifferentiated pleomorphic soft tissue sarcoma. Noting that immunotherapy for soft tissue sarcoma (STS) has ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. A 56-year-old man presented to the ED with 3 months of ...
Iovance Biotherapeutics Inc. (NASDAQ:IOVA) is one of the best get-rich-quick stocks to buy according to hedge funds. On February 24, Iovance Biotherapeutics announced positive early data from a pilot ...
Please provide your email address to receive an email when new articles are posted on . A phase 2 trial conducted by researchers at The University of Texas MD Anderson Cancer Center demonstrated the ...
Asianet Newsable on MSN
Why did IOVA stock gain pre-market today?
The company announced encouraging early results from a pilot study evaluating its tumor-infiltrating lymphocyte therapy, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results